Welcome to our dedicated page for Relief Hldg news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on Relief Hldg stock.
Relief Therapeutics Holding SA (OTCQB: RLFTF), historically known as Relief Therapeutics, regularly issues news updates covering its biopharmaceutical pipeline, corporate milestones, and, more recently, its transformation into MindMaze Therapeutics Holding SA through a business combination with NeuroX Group SA. Company press releases describe a focus on rare dermatological, metabolic, and respiratory diseases, along with digital neurotherapeutics and an AI-powered brain health platform following the combination.
News items for RLFTF include clinical and regulatory developments such as FDA designations and meeting outcomes for RLF-TD011 in epidermolysis bullosa, and pivotal bioequivalence study results for RLF-OD032, a liquid sapropterin formulation for phenylketonuria. Investors and observers can also find updates on corporate governance events like annual general meetings, half-year and annual report publications, and shareholder approvals for strategic transactions.
Coverage further extends to transaction-related announcements, including the proposed and completed business combination with NeuroX, details on share exchanges, and the renaming of the company to MindMaze Therapeutics Holding SA. Subsequent communications describe the combined company’s activities in digital neurorehabilitation and neurological care, while noting that it continues to manage Relief’s preexisting biopharmaceutical assets.
By following RLFTF news, readers can track the evolution of Relief’s rare disease programs, its regulatory interactions, and the integration of its portfolio into the broader MindMaze Therapeutics platform. This news stream provides context on how the company positions its therapies and digital technologies within the rare disease and neurology landscapes.
Relief Therapeutics has announced several executive changes. Interim CEO Michelle Lock's contract expired on May 31, 2024, and she will not seek re-election to the Board of Directors. CFO Andrew Einhorn and CHRO Melinda Keegan have also departed. The Board of Directors will oversee the company's operations while evaluating options to optimize the senior management team. Jeremy Meinen will remain in a senior role. The Board is focused on maximizing the value of Relief Therapeutics' therapeutic product portfolio.
Relief Therapeutics has announced its Annual General Meeting (AGM) of shareholders, scheduled for June 27, 2024, at 11:00 a.m. CEST in Geneva, Switzerland. The agenda includes key items such as the adoption of the 2023 annual report and financial accounts, appropriation of the annual result, discharge of the board of directors and executive committee, approval of compensation for board members, re-election of existing board members and its chairman, and election of the nomination and compensation committee. Shareholders will also vote on the 2023 compensation report and re-elect the independent voting rights representative and auditors. The formal notice, including attendance details and registration requirements, will be sent to registered shareholders on June 5, 2024. The full agenda is available on the Relief website.
Relief Therapeutics, a biopharmaceutical company, announced a new executive leadership team, appointing a chief financial officer, chief human resources officer, and head of legal and compliance. The new team includes Andrew Einhorn as CFO, Melinda Keegan as chief human resources officer, Giorgio Reiner as chief scientific officer, Paolo Galfetti as chief business officer, and Vincenzo Gallo as head of legal and compliance. Jeremy Meinen will step down as CFO. The company aims to accelerate its future success in rare diseases with an expected cash runway into 2026.
Relief Therapeutics, a biopharmaceutical company, has published its Annual Report for 2023 and provided a corporate update. The company is focused on delivering innovative treatment options for rare diseases. The interim CEO, Michelle Lock, expressed confidence in the company's strategic approach and highlighted the potential of RLF-TD011 for epidermolysis bullosa and RLF-OD032 for phenylketonuria.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Relief Hldg (RLFTF)?
What is the market cap of Relief Hldg (RLFTF)?
